Profile data is unavailable for this security.
About the company
International Biotechnology Trust plc is a United Kingdom-based investment trust company. The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company seeks to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialization of a product, device or enabling technology. The Company’s investments may also be made in related sectors, such as medical devices and healthcare services. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. SV Health Managers LLP is the Company's alternative investment fund manager (AIFM).
- Revenue in GBP (TTM)44.54m
- Net income in GBP38.88m
- Incorporated1994
- Employees0.00
- LocationInternational Biotechnology Trust6th Floor, 65 Gresham Street,LONDON EC2V 7NQUnited KingdomGBR
- Phone+44 20 7421 7070
- Websitehttps://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/international-biotechnology-trust/
Profile
| Management group(s) | Schroder Unit Trusts Limited |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GB0004559349 |
| Launch date | 06 May 1994 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Managed by
| Ailsa Craig, Marek Poszepczynski |
|---|
Management & contract fees
Management fee payable monthly at the rate of 0.7% p.a. of the NAV. The performance fee on the unquoted pool is 20% of net realised gain; performance fee on the quoted pool is 10% of relative outperformance above the sterling-adjusted NBI plus a 0.5% hurdle. Investment Management Agreement is terminable by either party on 12 months’ written notice.
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| INVESCO Asia Trust plc | 9.84m | 5.56m |
| Martin Currie Global Portfolio Trust PLC | 18.46m | 15.85m |
| TwentyFour Select Monthly Income Fnd Ltd | 40.25m | 37.93m |
| British Smaller Companies VCT plc | 14.57m | 10.62m |
| abrdn European Logistics Income PLC | 33.63m | -55.43m |
| Baillie Gifford UK Growth Trust PLC | 3.41m | 389.00k |
| International Biotechnology Trust Plc | 44.54m | 38.88m |
| Foresight Ventures VCT PLC | -3.64m | -6.72m |
| CC Japan Income and Growth Trust PLC | 64.60m | 60.78m |
| Taylor Maritime Investments Ltd | -33.60m | -42.27m |
| Gore Street Energy Storage Fund PLC | 2.27m | -5.66m |
| Intuitive Investments Group PLC | 824.00k | -865.00k |
| Montanaro European Smllr Cmpns Trst PLC | 18.37m | 14.63m |
| Blackstone Loan Financing Ltd | 86.44m | 85.24m |
| B.P. Marsh & Partners plc | 66.35m | 53.60m |
| Tufton Assets Ltd | 63.67m | 60.13m |
